Eli Lilly licensed worldwide rights to Adocia's BioChaperone Lispro ultra-rapid insulin for $50M upfront plus up to $280M in development milestones, $240M in sales milestones and tiered royalties. Lilly later terminated the alliance in 2017, triggering a multi-year arbitration ultimately decided in Lilly's favor.
Key facts
AnnouncedApr 30, 2014
ClosedMay 13, 2014
Deal value$570M
Deal typeLicensing/Option
Therapeutic areaType 1 and type 2 diabetes mellitus